Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567370 · ClinicalTrials.gov registry record · Phase 1
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02567370: Completed Phase 1 study, sponsored by Amgen.
NCT02567370 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02567370, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
Primary Outcome
Number and percent of subjects experiencing adverse events
Interventions
- DRUG Placebo
- DRUG AMG 581
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
What the finished NCT02567370 record still lists
NCT02567370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02567370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02567370 about?
NCT02567370 is a clinical study titled "Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581". The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
What is the current status of trial NCT02567370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02567370?
The interventions under investigation include: Placebo (DRUG), AMG 581 (DRUG).
Who is sponsoring clinical trial NCT02567370?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02567370's enrollment target sits among peer trials
70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia